Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1449, Issue 2, 1999, Pages 137-149

  Bassa, Babu V ^a,b   Roh, Daeyoung D ^a,b   Vaziri, Nosratola D ^b   Kirschenbaum, Michael A ^a,b   Kamanna, Vaijinath S ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell proliferation; Farnesol; Isoprenoid; Lovastatin; Mevalonate; Mitogenic signaling event

Indexed keywords

EPIDERMAL GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MEVALONIC ACID; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; RAS PROTEIN;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ISOPRENYLATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MESANGIUM; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL DIVISION; CELL LINE; CELLS, CULTURED; CHOLESTEROL; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLOMERULAR MESANGIUM; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MAP KINASE KINASE KINASES; MEVALONIC ACID; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PLATELET-DERIVED GROWTH FACTOR; POLYISOPRENYL PHOSPHATES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

MURINAE;

EID: 0032985265     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4889(99)00007-5     Document Type: Article

References (51)

1. R.J. Glassock, S.G. Adler, H.J. Ward, A.H. Cohen, Primary glomerular diseases, in: B.M. Brenner, F.C. Rector (Eds.), The Kidney, Saunders, Philadelphia, 1991, pp. 1182-1279.
2. Floege J., Burns M.W., Alpers C.E., Yoshimura A., Pritzl P., Gordon K., Seifert R.A., Bowen-Pope D.F., Couser W.G., Johnson R.J. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int. 41:1992;297-309.
3. Floege J., Eng E., Young B.A., Alpers C.E., Barrett T.B., Bowen-Pope D.F., Johnson R.J. Infusion of PDGF or basic FGF induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J. Clin. Invest. 92:1993;2952-2962.
4. Abboud H.E. Role of platelet-derived growth factor in renal injury. Annu. Rev. Physiol. 57:1995;297-309.
5. Kaysen G.A. Hyperlipidemia of the nephrotic syndrome. Kidney Int. Suppl 31:1991;S8-S15.
6. Kamanna V.S., Roh D.D., Kirschenbaum M.A. Atherogenic lipoproteins mediators of glomerular injury. Am. J. Nephrol. 13:1993;1-5.
7. Moorhead J.F., El-Nahas M., Chan M.K., Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 2:1982;1309-1311.
8. Keane W.F., Kasiske B.L., O'Donnell M.P. Lipids and progressive glomerulosclerosis. Am. J. Nephrol. 8:1988;261-271.
9. Diamond J.R. A putative role of hypercholesterolemia in progressive glomerular injury. Annu. Rev. Med. 43:1992;83-92.
10. Kasiske B.L., O'Donnell M.P., Cleary M.P., Keane W.F. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 33:1988;667-672.
11. Harris K.P.G., Purkerson M.L., Yates J., Klahr S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am. J. Kidney Dis. 15:1990;16-23.
12. Kasiske B.L., O'Donnell M.P., Gravis W.J., Keane W.F. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ. Res. 62:1988;367-374.
13. Fairbanks K.P., Larry D.W., Goodman D.S. Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J. Biol. Chem. 259:1984;1546-1551.
14. Habenicht A.J.R., Glomset J.A., Ross R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J. Biol. Chem. 255:1980;5134-5140.
15. Quesney-Huneeus V., Wiley M.H., Siperstein M.D. Essential role for mevalonate synthesis in DNA replication. Proc. Natl. Acad. Sci. U.S.A. 76:1979;5056-5060.
16. Quesney-Huneeus V., Galick H.A., Siperstein M.D., Erickson S.K., Spencer T.A., Nelson J.A. The dual role of mevalonate in the cell cycle. J. Biol. Chem. 258:1983;378-385.
17. Goldstein J.L., Helgeson J.A.S., Brown M.S. Inhibition of cholesterol synthesis with compactin renders growth of cultured cells dependent on the low density lipoprotein receptor. J. Biol. Chem. 254:1979;5403-5409.
18. O'Donnell M.P., Kasiske B.L., Kim Y., Durgaprasadsrao A., Keane W.F. Lovastatin inhibits proliferation of rat mesangial cells. J. Clin. Invest. 91:1993;83-87.
19. Grandaliano G., Biswas P., Choudhury G.G., Abboud H.E. Simvastatin inhibits PDGF-induced DNA synthesis in human gomerular mesangial cells. Kidney Int. 44:1993;503-508.
20. Casey P.J., Solski P.A., Der C.J., Buss J.E. p21 ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. U.S.A. 86:1989;8323-8327.
21. Kiyoko K., Adrienne D.C., Hisaka M.M., Graham S.M., Buss J.E., Der C.H. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. U.S.A. 89:1992;6403-6407.
22. Mizuno T., Kaibuchi K., Yamamoto T., Kawamura M., Sakoda T., Fujioka H., Matsuura Y., Takai Y. A stimulatory GDP/GTP exchange protein for smg p21 is active on the post-translationally processed form of c-Ki-ras p21 and rhoA p21. Proc. Natl. Acad. Sci. U.S.A. 88:1991;6442-6446.
23. ras. Science. 243:1990;67-69.
24. Vojtek A.B., Hollenberg S.M., Cooper J.A. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell. 74:1993;205-214.
25. Marshall M.S. Ras target proteins in eukaryotic cells. FASEB J. 9:1995;1311-1318.
26. i-coupled acetylcholine muscarinic m2 receptor activation of mitogen-activated protein (MAP) kinase kinase and MAP kinase. J. Biol. Chem. 268:1993;19196-19199.
27. Kawata S., Nagase T., Yamasaki E., Ishiguro H., Matsuzawa Y. Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2). Br. J. Cancer. 69:1994;1015-1020.
28. Jakobisiak M., Bruno S., Skierski J.S., Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. U.S.A. 88:1991;3628-3632.
29. Seger R., Krebs E.G. The MAPK signalling cascade. FASEB J. 9:1995;726-735.
30. Davis R.J. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268:1993;14553-14556.
31. Traverse S., Gomez N., Paterson H., Marshall C., Cohen P. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells, comparison of the effects of nerve growth factor and epidermal growth factor. Biochem. J. 288:1992;351-355.
32. Treisman R. Regulation of transcription by MAP kinase cascades. Curr. Opin. Cell Biol. 8:1996;205-215.
33. Kita T., Brown M.S., Goldstein J.L. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J. Clin. Invest. 66:1980;1094-1100.
34. Sturgill T.W., Ray L.B., Anderson N.G., Erickson A.K. Methods Enzymol. 200:1991;342-351.
35. ras upon T-cell activation. Nature. 346:1990;719-723.
36. Lerner E.C., Qian Y., Hamilton A.D., Sebti S.M. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J. Biol. Chem. 270:1995;26770-26773.
37. Jackson J.H., Cochrane C.G., Bourne J.R., Solski P.A., Buss J.E., Der C.J. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. U.S.A. 87:1990;3042-3046.
38. Crowell P.L., Chang R.R., Ren Z., Elson C.E., Gould M.N. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J. Biol. Chem. 266:1991;17679-17685.
39. Xu X., McGuire T.F., Blaskovich M.A., Sebti S.M., Romero G. Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts. Arch. Biochem. Biophys. 326:1996;233-237.
40. McGuire T.F., Qian Y., Vogt A., Hamilton A.D., Sebti S.M. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J. Biol. Chem. 271:1996;27402-27407.
41. Hirai A., Nakamura S., Noguchi Y., Yasuda T., Kitagawa M., Tatsuno I., Oeda T., Tahara K., Terano T., Narumiya S., Kohn L.D., Saito Y. Geranylgeranylated Rho small GTPase(s) are essential for the degradation of p27kip1 and facilitates the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J. Biol. Chem. 272:1997;13-16.
42. Gesualdo L., Pinzani M., Floriano J.J., Hassan M.O., Nugy N.U., Schena F.P., Emancipator S.N., Abboud H.E. Platelet-derived growth factor expression in mesangial proliferative glomerulonephritis. Lab. Invest. 65:1991;160-167.
43. Fellstrom B., Klareskog L., Heldin C.H., Larsson E., Ronnstrand L., Terracio L., Tufveson G., Wahlberg J., Rubin K. Platelet-derived growth factor receptors in the kidney, upregulated expression in inflammation. Kidney Int. 36:1989;1099-1102.
44. Iida H., Seifert R., Alpers C.E., Gronwald R.G.K., Phillips P.E., Pritzl P., Gordon K., Gown A.M., Ross R., Bowen-Pope D.F., Johnson R.J. Platelet-derived growth factor and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc. Natl. Acad. Sci. U.S.A. 88:1991;6560-6564.
45. Kamanna V.S., Bassa B.V., Kirschenbaum M.A. Atherogenic lipoproteins and human disease: extending concepts beyond the heart to the kidney. Curr. Opin. Nephrol. Hypertens. 6:1997;205-211.
46. Egido J., Gomez-Chiarri M., Ortiz A., Bustos C., Alonso J., Gomez-Guerrero C., Gomez-Garre D., Lopez-Armada M.S., Plaza J., Gonzalez E. Role of tumor necrosis factor-α in the pathogenesis of glomerular diseases. Kidney Int. 43:1993;S59-S64.
47. Battegay E.J., Raines E.W., Colbert T., Ross R. TNF-α stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and PDGF receptor expression. J. Immunol. 154:1995;6040-6047.
48. Ha H., Roh D.D., Kirschenbaum M.A., Kamanna V.S. Atherogenic lipoproteins enhance mesangial cell PDGF expression. Role of protein tyrosine kinase and cyclic AMP dependent protein kinase A. J. Lab. Clin. Med. 131:1998;456-465.
49. Grone E.F., Abboud H.E., Hohne M., Walli A.K., Grone H.J., Stuker D., Robenek H., Wieland E., Seidel D. Actions of lipoproteins in cultured human mesangial cells, modulation by mitogenic vasoconstrictors. Am. J. Physiol. 263:1992;F686-F696.
50. Stiko-Rahm A., Hultgardh-Nilsson A., Regnstrom J., Hamsten A., Nilsson J. Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arterioscl. Thromb. 12:1992;1099-1109.
51. Kamanna V.S., Pai R., Roh D.D., Kirschenbaum M.A. Oxidative modification of low density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation and proliferation. Lab. Invest. 74:1996;1067-1079.